{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:02:17Z","timestamp":1762160537629,"version":"3.40.4"},"reference-count":13,"publisher":"S. Karger AG","issue":"2","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Haematol"],"published-print":{"date-parts":[[2006]]},"abstract":"<jats:p>Little evidence exists regarding the prognostic impact of the major BCR-ABL gene variants (e13a2 and e14a2) in chronic myeloid leukemia (CML) patients diagnosed and treated in the developing Asian countries. In this study, 139 Thai CML patients were followed for a median period of 3 years (range 18\u201343 months). Clinical presentations of both BCR-ABL gene variant groups (73% e14a2+ and 27% e13a2+) were similar, although e14a2+ patients tended to be older (42 vs. 37 years) and had higher white blood cell counts than e13a2+ patients. The majority of patients in both groups presented with Sokal stage 2\u20133 (score &gt;0.8) and were categorized as Hasford\u2019s intermediate- to high-risk groups (score &gt;780). All patients received oral chemotherapy and 13% underwent allogeneic stem cell transplantation. None received oral tyrosine kinase inhibitors. In the conventional chemotherapy group, the overall survival (OS) rate was slightly better in e14a2+ than in e13a2+ patients (p = n.s.). The median survival in e14a2+ and e13a2+ patients who did not receive stem cell transplantation was 49 and 33 months, respectively (p = n.s.). The type of blastic crisis in e14a2+ and e13a2+ patients was similar, being predominantly myeloid. In conclusion, CML patients in Thailand, despite being much younger, had a comparable OS with those in the Western countries, with no different OS between e14a2+ and e13a2+ patients. Future studies should focus on the impact of novel oral BCR-ABL tyrosine kinase inhibitors on the outcome of Thai CML patients with different BCR-ABL gene variants.<\/jats:p>","DOI":"10.1159\/000093641","type":"journal-article","created":{"date-parts":[[2006,8,16]],"date-time":"2006-08-16T09:47:31Z","timestamp":1155721651000},"page":"114-119","source":"Crossref","is-referenced-by-count":5,"title":["Natural History of Southeast Asian Chronic Myeloid Leukemia Patients with Different BCR-ABL Gene Variants"],"prefix":"10.1159","volume":"116","author":[{"given":"C.U.","family":"Auewarakul","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Yimyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Boonmoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2006,8,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038%2F243290a0"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1006%2Fgeno.1995.1008"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJM199904293401706"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007%2FBF02983559"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2141.1989.tb07653.x"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2141.1995.tb08362.x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2141.1993.tb03062.x"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1365-2141.1990.tb02534.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016%2FS0037-1963%2803%2970038-9"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016%2Fj.hoc.2004.03.011"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2141.1997.d01-1982.x"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046%2Fj.1365-2141.2000.02229.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2004-08-3097"}],"container-title":["Acta Haematologica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/93641","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/93641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T03:14:08Z","timestamp":1745464448000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000093641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":13,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2006,8,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000093641","archive":["Portico"],"relation":{},"ISSN":["0001-5792","1421-9662"],"issn-type":[{"type":"print","value":"0001-5792"},{"type":"electronic","value":"1421-9662"}],"subject":[],"published":{"date-parts":[[2006]]}}}